ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Dr. Bernhard Helps Doctors in Underserved Areas Via the MAVEN Project

Carol Patton  |  June 15, 2020

In 2018, Gerson Bernhard, MD, FACP, MACR, received a call from a primary care physician at a rural clinic in Florida who was treating patients with varying degrees of arthritis. One patient’s case was more complex than the others. Dr. Bernhard guided the doctor through the patient’s history, reviewed lab results, referred related studies, expanded…

Filed under:ProfilesRheum After 5 Tagged with:Dr. Gerson BernhardMAVENUnderserved Patients

A Peaceful Medical Mission in Guatemala, Days before COVID-19

Daniel F. Battafarano, DO, MACP, FACR  |  June 15, 2020

My first-ever medical mission trip, after 37 years of medical practice, was to Teleman, Alta Verapaz, Guatemala. Prior to the trip, my excitement as an adult-trained rheumatologist was balanced against my apprehension about witnessing new diseases, caring for children and practicing in an austere environment with limited medical resources. As directed by the travel clinic,…

Filed under:Career Development Tagged with:medical missionsVolunteering

Case Report: Which Vasculitis Is It?

Mary Buckley, MD, & Jeffrey Dvergsten, MD  |  June 15, 2020

A 13-year-old, adopted girl of unknown ancestry with social anxiety, selective mutism and Takayasu arteritis presented for evaluation of severe, painful, gingival hyperplasia, which limited her oral intake and resulted in weight loss. The young patient was diagnosed with Takayasu arteritis at age 8, when she presented with a persistently elevated erythrocyte sedimentation rate (ESR),…

Filed under:ConditionsVasculitis Tagged with:Behçet’s diseasecase reportTakayasu arteritis (TAK)

Novel Cathepsin K Inhibitor Promising for OA

Lara C. Pullen, PhD  |  June 10, 2020

Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:cathepsin-K inhibitorKnee Osteoarthritis (OA)OsteoarthritisPain

FDA Approves Celecoxib in an Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  June 8, 2020

The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…

Filed under:AnalgesicsDrug Updates Tagged with:celecoxib (Elyxyb)FDAPain ManagementU.S. Food and Drug Administration (FDA)

In the Lungs: Asthma & COPD May Be Early, Independent Risk Factors for RA

Carina Stanton  |  June 1, 2020

Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…

Filed under:ConditionsRheumatoid Arthritis Tagged with:2019 ACR/ARP Annual Meetingasthmachronic obstructive pulmonary disorderCOPDlungs

Driving through the Storm: A Pediatric Rheumatologist Finds a Pandemic of Rheumatic Disease

Mark Gorelik, MD  |  May 18, 2020

A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.

Filed under:ConditionsOpinionSpeak Out Rheum Tagged with:COVID-19Pediatrics

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

Lara C. Pullen, PhD  |  May 18, 2020

Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…

Filed under:ConditionsPsoriatic Arthritis Tagged with:apremilastcDAPSAClinical Disease Activity in Psoriatic Arthritis (cDAPSA)PsApsoriatic arthritis

Andrey_Popov / shutterstock.com

How Ageism Hurts Physicians & Patients

Steven M. Harris, Esq.  |  May 15, 2020

Ageism is defined as stereo­typing, prejudice or discrimination against individuals on the basis of their age. According to the American Medical Association (AMA), 43% of all physicians and surgeons are 55 or older. Specialists are, on average, older than primary care doctors. In addition, around 30% of the current U.S. population is older than 55,…

Filed under:EthicsLegal Updates Tagged with:ageism

LeoWolfert / shutterstock.com

Precision Medicine Today: Predicting Treatment Response in Patient Subgroups

Carina Stanton  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—Choosing the right treatment at the right time is the brass ring all rheumatologists hope for. Precision medicine provides the ability to leverage clinical, biomarker and omics data to predict and personalize future treatment for rheumatoid arthritis (RA). “New data and new methods to analyze the data are helping us better predict patterns…

Filed under:ConditionsPatient PerspectiveRheumatoid Arthritis Tagged with:Precision MedicineWinter Rheumatology Summit

  • « Previous Page
  • 1
  • …
  • 81
  • 82
  • 83
  • 84
  • 85
  • …
  • 247
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences